Trial Profile

A Randomized Withdrawal Double-blind Study of Etanercept Monotherapy Compared to Methotrexate Monotherapy for Maintenance of Remission in Subjects With Rheumatoid Arthritis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Etanercept (Primary) ; Methotrexate
Indications Rheumatoid arthritis
Focus Registrational; Therapeutic Use
Acronyms SEAM-RA
Sponsors Amgen

Most Recent Events

24 Oct 2022 Results(n=253) assessing patient-reported outcomes rheumatoid arthritis following medication withdrawal and disease worsening changes in patients with published in the JCR: Journal of Clinical Rheumatology
05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism
18 Nov 2020 Primary endpoint (Simplified Disease Activity Index (SDAI) remission ( 3.3) at week 48) has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com